Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Rheumatology
Volume 2015, Article ID 795242, 8 pages
http://dx.doi.org/10.1155/2015/795242
Case Report

A Case of Docetaxel Induced Myositis and Review of the Literature

1Department of Medicine, St. Luke’s-Roosevelt Hospital Center, and Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10025, USA
2Division of Rheumatology, Department of Medicine, St. Luke’s-Roosevelt Hospital Center, and Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10025, USA

Received 23 March 2015; Revised 12 June 2015; Accepted 22 June 2015

Academic Editor: Toshiaki Takahashi

Copyright © 2015 Alexandra Perel-Winkler et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. American Cancer Society, Cancer Facts and Figures 2014, 2014, http://www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc-042151.pdf.
  2. A. S. Ardavanis, G. N. Ioannidis, and G. A. Rigatos, “Acute myopathy in a patient with lung adenocarcinoma treated with gemcitabine and docetaxel,” Anticancer Research, vol. 25, no. 1, pp. 523–525, 2005. View at Google Scholar · View at Scopus
  3. B. G. M. Hughes and R. Stuart-Harris, “Docetaxel-induced myositis: report of a novel side-effect,” Internal Medicine Journal, vol. 35, no. 6, pp. 369–370, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Gidron, M. Quadrini, N. Dimov, and A. Argiris, “Malignant thymoma associated with fatal myocarditis and polymyositis in a 32-year-old woman with a history of hairy cell leukemia,” American Journal of Clinical Oncology, vol. 29, no. 2, pp. 213–214, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Fardet, P.-E. Stoebner, H. Bachelez et al., “Treatment with taxanes of refractory or life-threatening Kaposi sarcoma not associated with human immunodeficiency virus infection,” Cancer, vol. 106, no. 8, pp. 1785–1789, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Kalmadi, G. McNeill, M. Davis, D. Peereboom, D. Adelstein, and T. Mekhail, “Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer,” Medical Oncology, vol. 23, no. 4, pp. 507–513, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Sasaki, M. Yano, O. Kawano, Y. Hikosaka, and Y. Fujii, “Thymoma associated with fatal myocarditis and polymyositis in a 58-year-old man following treatment with carboplatin and paclitaxel: a case report,” Oncology Letters, vol. 3, no. 2, pp. 300–302, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. R. R. Winkelmann, J. A. Yiannias, D. J. Dicaudo et al., “Paclitaxel-induced diffuse cutaneous sclerosis: a case with associated esophageal dysmotility, Raynaud's phenomenon, and myositis,” The International Journal of Dermatology, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. A. C. Perel-Winkler and C. T. Derk, “Diffuse cutaneous mucinosis in dermatomyositis: a case report and review of the literature,” Case Reports in Dermatological Medicine, vol. 2014, Article ID 938414, 6 pages, 2014. View at Publisher · View at Google Scholar
  10. L. S. Bachegowda, D. F. Makower, and J. A. Sparano, “Taxanes: impact on breast cancer therapy,” Anti-Cancer Drugs, vol. 25, no. 5, pp. 512–521, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. P. H. E. Hilkens, J. Verweij, G. Stoter, C. J. Vecht, W. L. J. van Putten, and M. J. van den Bent, “Peripheral neurotoxicity induced by docetaxel,” Neurology, vol. 46, no. 1, pp. 104–108, 1996. View at Publisher · View at Google Scholar · View at Scopus
  12. P. H. E. Hilkens, L. C. Pronk, J. Verweij, C. J. Vecht, W. L. J. Van Putten, and M. J. Van Den Bent, “Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin,” British Journal of Cancer, vol. 75, no. 3, pp. 417–422, 1997. View at Publisher · View at Google Scholar · View at Scopus
  13. P. H. Wiernik, E. L. Schwartz, J. J. Strauman, J. P. Dutcher, R. B. Lipton, and E. Paietta, “Phase I clinical and pharmacokinetic study of taxol,” Cancer Research, vol. 47, no. 9, pp. 2486–2493, 1987. View at Google Scholar · View at Scopus
  14. R. C. Donehower, E. K. Rowinsky, L. B. Grochow, S. M. Longnecker, and D. S. Ettinger, “Phase I trial of taxol in patients with advanced cancer,” Cancer Treatment Reports, vol. 71, no. 12, pp. 1171–1177, 1987. View at Google Scholar · View at Scopus
  15. A. Sulkes, U. Beller, T. Peretz et al., “Taxol: initial Israeli experience with a novel anticancer agent,” Israel Journal of Medical Sciences, vol. 30, no. 1, pp. 70–78, 1994. View at Google Scholar · View at Scopus
  16. V. Valero, F. A. Holmes, R. S. Walters et al., “Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline resistant metastatic breast cancer,” Journal of Clinical Oncology, vol. 13, no. 12, pp. 2886–2894, 1995. View at Google Scholar · View at Scopus
  17. G. Giaccone, M. Huizing, W. T. B. Huinink et al., “Preliminary results of two dose-finding studies of paclitaxel (taxol) and carboplatin in non-small cell lung and ovarian cancer: a European Cancer Center effort,” Seminars in Oncology, vol. 21, no. 5, pp. 34–38, 1994. View at Google Scholar · View at Scopus
  18. E. K. Rowinsky, P. J. Burke, J. E. Karp, R. W. Tucker, D. S. Ettinger, and R. C. Donehower, “Phase I and pharmacodynamics study of taxol in refractory acute leukemias,” Cancer Research, vol. 49, no. 16, pp. 4640–4647, 1989. View at Google Scholar · View at Scopus
  19. S. Saibil, B. Fitzgerald, O. C. Freedman et al., “Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: a retrospective, outcomes-based survey,” Current Oncology, vol. 17, no. 4, pp. 42–47, 2010. View at Google Scholar · View at Scopus
  20. R. B. Lipton, S. C. Apfel, J. P. Dutcher et al., “Taxol produces a predominantly sensory neuropathy,” Neurology, vol. 39, no. 3, pp. 368–373, 1989. View at Publisher · View at Google Scholar · View at Scopus
  21. R. J. Freilich, C. Balmaceda, A. D. Seidman, M. Rubin, and L. M. DeAngelis, “Motor neuropathy due to docetaxel and paclitaxel,” Neurology, vol. 47, no. 1, pp. 115–118, 1996. View at Publisher · View at Google Scholar · View at Scopus
  22. J. P. Callen, “Myositis and malignancy,” Current Opinion in Rheumatology, vol. 6, no. 6, pp. 590–594, 1994. View at Publisher · View at Google Scholar · View at Scopus
  23. Z. A. Zahr and A. N. Baer, “Malignancy in myositis,” Current Rheumatology Reports, vol. 13, no. 3, pp. 208–215, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Koike, F. Tanaka, and G. Sobue, “Paraneoplastic neuropathy: wide-ranging clinicopathological manifestations,” Current Opinion in Neurology, vol. 24, no. 5, pp. 504–510, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. Nakao, M. Yokoyama, S. Nishiyama et al., “Pyomyositis associated with chemotherapy for endometrial cancer: a case report,” World Journal of Surgical Oncology, vol. 11, article 45, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. P. Singh, W. Chan, P. Blomfield, and R. McIntosh, “Pyomyositis after chemotherapy for endometrial cancer,” International Journal of Gynecological Cancer, vol. 20, no. 7, pp. 1256–1258, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. J. W. Albers and R. Pop-Busui, “Diabetic neuropathy: mechanisms, emerging treatments, and subtypes,” Current Neurology and Neuroscience Reports, vol. 14, no. 8, article 473, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. P. J. B. Dyck and A. J. Windebank, “Diabetic and nondiabetic lumbosacral radiculoplexus neuropathies: new insights into pathophysiology and treatment,” Muscle & Nerve, vol. 25, no. 4, pp. 477–491, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. B. Choudhury, U. Saikia, D. Sarma, M. Saikia, S. D. Choudhury, and D. Bhuyan, “Diabetic myonecrosis: an underreported complication of diabetes mellitus,” Indian Journal of Endocrinology and Metabolism, vol. 15, no. 5, pp. S58–S61, 2011. View at Publisher · View at Google Scholar
  30. W. B. Horton, J. S. Taylor, T. J. Ragland, and A. R. Subauste, “Diabetic muscle infarction: a systematic review,” BMJ Open Diabetes Research & Care, vol. 3, no. 1, 2015. View at Publisher · View at Google Scholar
  31. M. Schulze, I. Kötter, U. Ernemann et al., “MRI findings in inflammatory muscle diseases and their noninflammatory mimics,” American Journal of Roentgenology, vol. 192, no. 6, pp. 1708–1716, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. T. Klopstock, “Drug-induced myopathies,” Current Opinion in Neurology, vol. 21, no. 5, pp. 590–595, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. R. M. Pascuzzi, “Drugs and toxins associated with myopathies,” Current Opinion in Rheumatology, vol. 10, no. 6, pp. 511–520, 1998. View at Publisher · View at Google Scholar · View at Scopus
  34. A. L. Catapano, “Statin-induced myotoxicity: pharmacokinetic differences among statins and the risk of rhabdomyolysis, with particular reference to pitavastatin,” Current Vascular Pharmacology, vol. 10, no. 2, pp. 257–267, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. P. D. Thompson, P. Clarkson, and R. H. Karas, “Statin-associated myopathy,” Journal of the American Medical Association, vol. 289, no. 13, pp. 1681–1690, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. M. G. Mohaupt, R. H. Karas, E. B. Babiychuk et al., “Association between statin-associated myopathy and skeletal muscle damage,” Canadian Medical Association Journal, vol. 181, no. 1-2, pp. 11–18, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. E. K. Rowinsky, V. Chaudhry, A. A. Forastiere et al., “Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting,” Journal of Clinical Oncology, vol. 11, no. 10, pp. 2010–2020, 1993. View at Google Scholar · View at Scopus